Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives Average Rating of “Buy” from Analysts

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) has received an average rating of “Buy” from the nine ratings firms that are presently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, five have given a buy recommendation and three have issued a strong buy recommendation on the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $11.33.

Several equities research analysts have recently weighed in on the company. Canaccord Genuity Group assumed coverage on Aclaris Therapeutics in a research report on Tuesday, September 1st. They issued a “buy” rating and a $10.00 target price for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Aclaris Therapeutics in a research report on Monday, September 21st. Finally, Wall Street Zen cut Aclaris Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday.

Aclaris Therapeutics Price Performance

Aclaris Therapeutics stock opened at $4.39 on Wednesday. The firm has a fifty day moving average of $5.73 and a 200-day moving average of $4.97. Aclaris Therapeutics has a 52-week low of $1.74 and a 52-week high of $6.60. The firm has a market capitalization of $613.81 million, a P/E ratio of -7.57 and a beta of 0.87.

Aclaris Therapeutics (NASDAQ:ACRS) last posted its earnings results on Thursday, August 6th. The biotechnology company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.16) by $0.01. Aclaris Therapeutics had a negative net margin of 921.50% and a negative return on equity of 61.65%. The business had revenue of $1.63 million for the quarter, compared to analyst estimates of $1.38 million. On average, research analysts expect that Aclaris Therapeutics will post -0.62 EPS for the current fiscal year.

Institutional Investors Weigh In On Aclaris Therapeutics

A number of large investors have recently added to or reduced their stakes in the company. Sei Investments Co. purchased a new position in Aclaris Therapeutics in the 1st quarter valued at about $814,000. Bank of New York Mellon Corp purchased a new stake in shares of Aclaris Therapeutics during the second quarter worth about $1,495,000. Dimensional Fund Advisors LP increased its position in shares of Aclaris Therapeutics by 88.8% during the first quarter. Dimensional Fund Advisors LP now owns 511,461 shares of the biotechnology company’s stock worth $1,914,000 after acquiring an additional 240,611 shares during the last quarter. Kalehua Capital Management LLC acquired a new position in shares of Aclaris Therapeutics in the first quarter worth about $6,871,000. Finally, Deutsche Bank AG acquired a new position in shares of Aclaris Therapeutics in the second quarter worth about $5,507,000. 98.34% of the stock is owned by institutional investors and hedge funds.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for immune-mediated diseases. The company’s research programs have centered on small-molecule treatments designed to address inflammatory and autoimmune conditions, including dermatologic and rheumatologic diseases.

Aclaris’ lead investigational program is zunsemetinib (ATI-450), an oral mitogen-activated protein kinase-activated protein kinase 2 (MK2) inhibitor being evaluated for potential use in inflammatory conditions such as rheumatoid arthritis and psoriasis.